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Erratum
The Abstracts Supplement to the February 2005 issue of BBMT included an abstract (No. 160, “Cross-
reactivity of Epstein Barr Virus-Specific Cytotoxic T Lymphocytes with an HLA-C Locus Allele”), sub-
mitted by Carolyn Keever-Taylor. This abstract has been withdrawn since the supplement went to press.
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